Michael Safdi

Statistics

Publications

Citations

4.6K

H-Index

Active since

1977

Affiliations

Atlanta Gastroenterology Associates(Current)

University of Chicago

Clinical Research Associates

Clinical Research Consultants (United States)

Mayo Clinic

Michael Safdi is an author at Atlanta Gastroenterology Associates specializing in inflammatory bowel disease, pharmacotherapy, and crohn disease pharmacotherapy.

Publications per year

1977–2018

Publications

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

William J. Sandborn, S. B. Hanauer, Seymour Katz et al. · Gastroenterology · 2001 · 911 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

Paul Rutgeerts, Robert H. Diamond, Mohan Bala et al. · Gastrointestinal Endoscopy · 2006 · 549 citations

Pharmacy, Pharmacotherapy, Gastrointestinal Pharmacotherapy +13

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Miguel Regueiro, Brian G. Feagan, Bin Zou et al. · Gastroenterology · 2016 · 329 citations · Full text

Medicine, Clinical Sciences, Surgery +14

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

Michael Safdi, Michael DeMicco, Charles A. Sninsky et al. · Gastroenterology · 1995 · 324 citations

Pharmacy, Pharmacotherapy, Gastroenterology +7

Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

Stephen B. Hanauer, William J. Sandborn, Asher Kornbluth et al. · The American Journal of Gastroenterology · 2005 · 323 citations

Medicine, Pharmacology, Pharmacotherapy +9

1–5 of 33